English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the discovery of monoclonal antibodies (Kohler & Milstein, 1975) much attention has been devoted to the development of reagents which would be of use in the detection and treatment of diseases, such as cancer and graft-versus-host disease resulting from human bone marrow allografts. This means that such antibodies are and will increasingly be used either in vivo in patients (Mathieu et al., 1984) or that cells from patients will be exposed to such antibodies for cytotoxic separation procedures prior to replacement into patients (Waldmann et al., 1984). As most large-scale productions of monoclonal antibodies are carried out using ascites preparations induced in either mice or rats, a question which needs careful consideration is whether rodent viruses which contaminate many colonies of laboratory animals and may contaminate hybridomas, will be present in such therapeutically used materials and, if so, whether they constitute an additional pathological threat to the patients undergoing therapy.

Is Rodent Virus Contamination of Monoclonal Antibody Preparations for Use in Human Therapy a Hazard?